Edgewise Therapeutics Inc. stock reached a significant milestone, hitting a 52-week high at $31.39. This achievement underscores the company’s strong performance over the past year, with the stock ...

Edgewise Therapeutics Inc. reports fourth-quarter results on Thursday, February 19, with investors weighing widening losses against the clinical-stage biotech’s progress toward what analysts call a ...

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Edgewise Therapeutics (EWTX) has been drawing attention ...

One of the more bullish analysts tracking the company reiterated her enthusiastic buy recommendation on the biotech. She has flagged it as one of her firm's best stock ideas for this year. In fact, ...

The analyst in question was Piper Sandler's Yasmeen Rahimi. Monday morning, she reiterated her overweight recommendation on Edgewise's equity and her $51 per share price target. Image source: Getty ...

Edgewise Therapeutics Inc. (NASDAQ: EWTX) on Wednesday shared updates from the ongoing CIRRUS-HCM Phase 2 trial of EDG-7500. EDG-7500 is an oral cardiac sarcomere modulator, specifically designed to ...

BOULDER, Colo., Dec. 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics ...

Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of ...

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is one of the best small-cap biotech stocks to buy according to analysts. Edgewise Therapeutics, Inc. (NASDAQ:EWTX) reported its Q3 2025 results on November 6 ...

An announcement from Edgewise Therapeutics ( (EWTX)) is now available. On November 10, 2025, Edgewise Therapeutics announced the appointment of Michael Nofi as Chief Financial Officer, succeeding ...